Leonie Klimpke
Directeur Financier/CFO chez Cavalry Ventures Management GmbH
Profil
Leonie Klimpke is currently the Head of Finance at Cavalry Ventures Management GmbH since 2022.
Previously, she worked as a Finance Manager at Eternygen GmbH from 2016 to 2020.
Ms. Klimpke completed her undergraduate degree at Vrije Universiteit Amsterdam in 2010 and her graduate degree at École des Hautes Études Commerciales de Paris in 2014.
Postes actifs de Leonie Klimpke
Sociétés | Poste | Début |
---|---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Directeur Financier/CFO | 01/02/2020 |
Anciens postes connus de Leonie Klimpke
Sociétés | Poste | Fin |
---|---|---|
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 28/02/2020 |
Formation de Leonie Klimpke
École des Hautes Études Commerciales de Paris | Graduate Degree |
Vrije Universiteit Amsterdam | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Finance |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |